Drugs / 1-(2-[18F]FLUOROETHYL)-L-Tryptophan
1-(2-[18F]FLUOROETHYL)-L-Tryptophan
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05556473 | Sep 2022 → Dec 2027 expected | brain glioma, breast cancer, metastatic malignant neoplasm in the brain, neuroendocrine neoplasm +1 | Barbara Ann Karmanos Cancer Institute | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 1-(2-[18F]FLUOROETHYL)-L-Tryptophan | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05556473 ↗ |
| Modality | Diagnostic / imaging agent | “PET radiotracer” NCT05556473 ↗ |
| Route | Other | “injection given one time prior to PET Scan.” NCT05556473 ↗ |